These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35977240)

  • 1. Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs.
    Keshwani S; Maguire M; Goodin A; Lo-Ciganic WH; Wilson DL; Hincapie-Castillo JM
    JAMA Health Forum; 2022 Jun; 3(6):e221757. PubMed ID: 35977240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder.
    Christine PJ; Larochelle MR; Lin LA; McBride J; Tipirneni R
    JAMA Health Forum; 2023 Oct; 4(10):e233549. PubMed ID: 37862034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphine Utilization and Prescribing Among New Jersey Medicaid Beneficiaries After Adoption of Initiatives Designed to Improve Treatment Access.
    Treitler P; Nowels M; Samples H; Crystal S
    JAMA Netw Open; 2023 May; 6(5):e2312030. PubMed ID: 37145594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thematic Analysis of State Medicaid Buprenorphine Prior Authorization Requirements.
    Nguemeni Tiako MJ; Dolan A; Abrams M; Oyekanmi K; Meisel Z; Aronowitz SV
    JAMA Netw Open; 2023 Jun; 6(6):e2318487. PubMed ID: 37318805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes.
    Hammerslag LR; Talbert J; Slavova S; Lei F; Freeman PR; Marks KR; Fanucchi LC; Walsh SL; Lofwall MR
    J Subst Use Addict Treat; 2024 Sep; 164():209391. PubMed ID: 38740189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.
    Wen H; Hockenberry JM; Pollack HA
    JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coverage and Prior Authorization Policies for Medications for Opioid Use Disorder in Medicaid Managed Care.
    Abraham AJ; Andrews CM; Harris SJ; Westlake MM; Grogan CM
    JAMA Health Forum; 2022 Nov; 3(11):e224001. PubMed ID: 36331441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States.
    Parish WJ; Mark TL; Zarkin GA; Weber E
    Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Formulary Prior Authorization Policies With Buprenorphine-Naloxone Prescriptions and Hospital and Emergency Department Use Among Medicare Beneficiaries.
    Mark TL; Parish WJ; Zarkin GA
    JAMA Netw Open; 2020 Apr; 3(4):e203132. PubMed ID: 32310285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes.
    Taylor EA; Cantor JH; Bradford AC; Simon K; Stein BD
    JAMA Netw Open; 2023 May; 6(5):e2314328. PubMed ID: 37204793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
    Burns RM; Pacula RL; Bauhoff S; Gordon AJ; Hendrikson H; Leslie DL; Stein BD
    Subst Abus; 2016; 37(1):63-9. PubMed ID: 26566761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion.
    Saloner B; Levin J; Chang HY; Jones C; Alexander GC
    JAMA Netw Open; 2018 Aug; 1(4):e181588. PubMed ID: 30646116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment.
    Stein BD; Saloner BK; Golan OK; Andraka-Christou B; Andrews CM; Dick AW; Davis CS; Sheng F; Gordon AJ
    JAMA Health Forum; 2023 May; 4(5):e231102. PubMed ID: 37234015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies.
    Landis RK; Opper I; Saloner B; Gordon AJ; Leslie DL; Sorbero M; Stein BD
    Drug Alcohol Depend; 2022 Dec; 241():109669. PubMed ID: 36332589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. State- and County-Level Geographic Variation in Opioid Use Disorder, Medication Treatment, and Opioid-Related Overdose Among Medicaid Enrollees.
    Lindner SR; Hart K; Manibusan B; McCarty D; McConnell KJ
    JAMA Health Forum; 2023 Jun; 4(6):e231574. PubMed ID: 37351873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Did the 2021 federal change in the practice guidelines for the administration of buprenorphine for treating opioid use disorder increase buprenorphine prescription dispensing in Medicaid population?
    Qian J; Khatiwada AP; Xue X
    Am J Addict; 2024 May; 33(3):335-338. PubMed ID: 38069608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Removal of prior authorization for medication-assisted treatment: impact on opioid use and policy implications in a Medicare Advantage population.
    Ferries E; Racsa P; Bizzell B; Rhodes C; Suehs B
    J Manag Care Spec Pharm; 2021 May; 27(5):596-606. PubMed ID: 33908274
    [No Abstract]   [Full Text] [Related]  

  • 18. Urine drug testing among Medicaid enrollees initiating buprenorphine treatment for opioid use disorder within 9 MODRN states.
    Hammerslag L; Talbert J; Donohue JM; Sharbaugh M; Ahrens K; Allen L; Austin AE; Gordon AJ; Jarlenski M; Kim JY; Mohamoud S; Tang L; Burns M;
    Drug Alcohol Depend; 2023 Sep; 250():110875. PubMed ID: 37413960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder.
    Mintz CM; Xu KY; Presnall NJ; Hartz SM; Levin FR; Scherrer JF; Bierut LJ; Grucza RA
    JAMA Netw Open; 2022 May; 5(5):e2211634. PubMed ID: 35544135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicaid Prescription Cap Policies: Another Structural Barrier to Medication for Opioid Use Disorder.
    Hughto JMW; Moyo P; Green TC
    J Addict Med; 2022 Nov-Dec 01; 16(6):616-618. PubMed ID: 35245915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.